Innovus Pharma Initiates Primate Safety Studies of Its Products That Affect Premature Ejaculation and Penile Sensation

LA JOLLA, Calif., July 3, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals Inc., ("Innovus Pharma") (OTCBB:INNV) today announced it started two studies in non-human primates to evaluate the safety of daily use of EjectDelay and CIRCUMserum.

EjectDelay is an over-the-counter (OTC) FDA compliant gel containing the active ingredient benzocaine, which transiently reduces penile sensation in order to treat premature ejaculation. CIRCUMserum is a personal care cream that increases penile sensitivity, enhancing the sexual experience.

The studies will determine if the products have any effect on the female partners of males that use the products. The studies will look for changes in vaginal flora, pH and the endometrium, the membrane that lines the uterus. If changes are detected, the studies will assess whether or not those changes are reversible.

Dr. Bassam Damaj, President and Chief Executive Officer of Innovus Pharma, said "Based on our previous work, we believe these products are both safe and effective for men. We expect these studies to also confirm that the products are safe for the men's female partners."

Innovus Pharma, headquartered in La Jolla, California, is an emerging pharmaceuticals company that delivers innovative and uniquely presented and packaged health solutions through its over-the-counter medicines and consumer and health products.

For more information, go to

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:

With the exception of the historical statements, statements contained in this release, including statements regarding the expected results of the studies, may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identifiable by the use of the words "believes," "views," "expects," "projects," "hopes," "could," "will," "intends," "should," "estimate," "would," "may," "anticipates," "plans", "target", "goal" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are subject to a number of risks and uncertainties that may, individually or collectively, cause actual results to differ materially from those contained in the forward-looking information, and are based on the current expectations, estimates, forecasts and projections of Innovus Pharma. Many of the risks and uncertainties are outside the control of Innovus Pharma. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in Innovus Pharma's most recent annual report on Form 10-K and its other filings with the SEC. Copies of these filings are available from the SEC's website or the "Investors" section of Innovus Pharma's website at Forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Innovus Pharma undertakes no obligation to publicly release the results of any revisions or updates to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

CONTACT: Innovus Pharma Contact: Kevin Holmes Chesapeake Group T: 410-825-3930Source:Innovus Pharmaceuticals, Inc.